Position
XPONANCE LLC in Arbutus Biopharma Corp
Back to the book · All holders of ABUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$3.68K$4.81 → $4.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 11.9K | $57.1K | — | — | — | 0.0% |
| Q1 2026 | 13.7K | $61.6K | $4.50 | −$3.68K | $8.16K | 0.0% |